Wellington Management Group LLP Acquires Shares of 19,723 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Wellington Management Group LLP bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 19,723 shares of the company’s stock, valued at approximately $957,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. GAMMA Investing LLC lifted its position in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after acquiring an additional 273 shares during the period. Innealta Capital LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth approximately $55,000. Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the period. Blue Trust Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. purchased a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at $78,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the sale, the director now owns 30,471 shares in the company, valued at $1,333,715.67. This represents a 24.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the transaction, the executive vice president now directly owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. This represents a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,533 shares of company stock valued at $1,987,482. Corporate insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $39.39 on Friday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92. The company has a 50-day simple moving average of $46.63 and a 200-day simple moving average of $44.56. The company has a market capitalization of $1.89 billion, a PE ratio of 13.13, a P/E/G ratio of 0.87 and a beta of 0.78.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective for the company. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $60.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.